Functional Rehabilitation and Group Education, Vienna
We are the ISO-9001 certified research group, headed by Professor Kinga Howorka, MD; non-profit organisation providing medical research, structured individual and group education for self-treatment in diabetes and related diseases.
Our main focus is diabetes mellitus with special interest in Type 1 diabetes, pregnancy in diabetes and/or hypoglycemia unawareness. Further on, components of metabolic syndrome such as hypertension, dyslipidemia and obesity are of particular interest, as well. Non-invasive medical aesthetics treatments, body contouring with radiofrequency and injection lipolysis, thread lifting and PRP (Platelets-Rich-Plasma / "Vampire-Lift") are our further fields of expertise within the concept of comprehensive antiaging.
Our offices are located in center of Vienna, Austria and we closely cooperate with Medical University of Vienna, Center of Medical Physics and Biomedical Engineering, as well as with other medical university research and/or pharmaceuticals research groups.
Functional Insulin Treatment means that insulin is used functionally to imitate insulin production in a healthy pancreas. It is used functionally by separate replacement of:
Basal
- insulin necessary to sustain the body while fasting, and
Prandial
- or meal-related insulin, and
Correction
insulin, necessary to lower blood glucose levels to the preferred target.
This system allows to adjust the insulin supply you need with 4 to 6 daily insulin injections or with an insulin pump. The insulin is personalized to individual requirements based on several daily blood glucose self-measurements (or a continuous glucose sensor), appetite (requirements for food) or fasting needs. Delayed-acting insulin (e.g., Lantus®, Tresiba® or Toujeo® (long-acting insulin analogs) injections or a pump is needed to cover basal or fasting insulin needs. Eating, or correcting high blood glucose levels requires a rapid-acting insulin.
NEWS
In Austria, new long-acting insulin analogs Tresiba® (NovoNordisk) and Toujeo®, U-300 insulin glargine (sanofi-aventis) are now available ("yellow box" in respect to reimbursement).
